Gemcitabine in advanced non-small cell lung cancer: A phase II study

Gemcitabine is an active agent for treatment of advanced nonsmall cell lung cancer (NSCLC). Weekly treatment with singleagent gemcitabine has shown response rates of 20% to 26%. This Phase II trial was conducted to determine the efficacy and safety of 1000 mg/m2 gemcitabine administered weekly for 3 weeks followed by 1 week or rest (28-day cycle). Patients were required to have histologic evide…